Stephen A Graves

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8489219/publications.pdf

Version: 2024-02-01

67	2,232	186265	233421
papers	citations	28 h-index	45 g-index

68	68	68	3489
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hexamodal Imaging with Porphyrinâ€Phospholipidâ€Coated Upconversion Nanoparticles. Advanced Materials, 2015, 27, 1785-1790.	21.0	189
2	In Vivo Tumor Vasculature Targeting of CuS@MSN Based Theranostic Nanomedicine. ACS Nano, 2015, 9, 3926-3934.	14.6	155
3	Preclinical Pharmacokinetics and Biodistribution Studies of ⁸⁹Zr-Labeled Pembrolizumab. Journal of Nuclear Medicine, 2017, 58, 162-168.	5.0	152
4	Red Fluorescent Zinc Oxide Nanoparticle: A Novel Platform for Cancer Targeting. ACS Applied Materials & Interfaces, 2015, 7, 3373-3381.	8.0	84
5	⁵²Mn Production for PET/MRI Tracking Of Human Stem Cells Expressing Divalent Metal Transporter 1 (DMT1). Theranostics, 2015, 5, 227-239.	10.0	80
6	Novel Preparation Methods of ⁵²Mn for ImmunoPET Imaging. Bioconjugate Chemistry, 2015, 26, 2118-2124.	3.6	74
7	Engineering Intrinsically Zirconiumâ€89 Radiolabeled Selfâ€Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies. Advanced Science, 2016, 3, 1600122.	11.2	70
8	Separation of cyclotron-produced 44Sc from a natural calcium target using a dipentyl pentylphosphonate functionalized extraction resin. Applied Radiation and Isotopes, 2015, 95, 23-29.	1.5	66
9	Dynamic Positron Emission Tomography Imaging of Renal Clearable Gold Nanoparticles. Small, 2016, 12, 2775-2782.	10.0	66
10	Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials, 2016, 100, 101-109.	11.4	61
11	Commissioning of a 1.5T Elekta Unity MRâ€linac: A single institution experience. Journal of Applied Clinical Medical Physics, 2020, 21, 160-172.	1.9	61
12	A porphyrin-PEG polymer with rapid renal clearance. Biomaterials, 2016, 76, 25-32.	11.4	60
13	Long circulating reduced graphene oxideâ€“iron oxide nanoparticles for efficient tumor targeting and multimodality imaging. Nanoscale, 2016, 8, 12683-12692.	5.6	58
14	Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12806-12811.	7.1	54
15	Targeting CD146 with a ⁶⁴ Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6525-34.	7.1	54
16	Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. ACS Applied Materials & Interfaces, 2016, 8, 17955-17963.	8.0	48
17	Radiolabeled, Antibody-Conjugated Manganese Oxide Nanoparticles for Tumor Vasculature Targeted Positron Emission Tomography and Magnetic Resonance Imaging. ACS Applied Materials & Interfaces, 2017, 9, 38304-38312.	8.0	47
18	Optimized procedures for manganese-52: Production, separation and radiolabeling. Applied Radiation and Isotopes, 2017, 121, 38-43.	1.5	37

#	Article	IF	Citations
19	ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1295-1303.	6.4	36
20	ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. Molecular Pharmaceutics, 2017, 14, 1646-1655.	4.6	36
21	PET Imaging of Abdominal Aortic Aneurysm with ⁶⁴Cu-Labeled Anti-CD105 Antibody Fab Fragment. Journal of Nuclear Medicine, 2015, 56, 927-932.	5.0	35
22	Isotope harvesting at FRIB: additional opportunities for scientific discovery. Journal of Physics G: Nuclear and Particle Physics, 2019, 46, 100501.	3.6	35
23	Radiomanganese PET Detects Changes in Functional Î²-Cell Mass in Mouse Models of Diabetes. Diabetes, 2017, 66, 2163-2174.	0.6	32
24	In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica Nanosystem. Nano-Micro Letters, 2018, 10, 65.	27.0	31
25	Dual Targeting of Tissue Factor and CD105 for Preclinical PET Imaging of Pancreatic Cancer. Clinical Cancer Research, 2016, 22, 3821-3830.	7.0	30
26	PET Imaging of VEGFR-2 Expression in Lung Cancer with ⁶⁴Cu-Labeled Ramucirumab. Journal of Nuclear Medicine, 2016, 57, 285-290.	5.0	30
27	Cyclotron production and radiochemical separation of 55Co and 58mCo from 54Fe, 58Ni and 57Fe targets. Applied Radiation and Isotopes, 2017, 130, 90-101.	1.5	30
28	Commissioning and performance evaluation of RadCalc for the Elekta unity MRIâ€linac. Journal of Applied Clinical Medical Physics, 2019, 20, 54-62.	1.9	30
29	Intrinsically Zirconium-89-Labeled Manganese Oxide Nanoparticles for In Vivo Dual-Modality Positron Emission Tomography and Magnetic Resonance Imaging. Journal of Biomedical Nanotechnology, 2018, 14, 900-909.	1.1	29
30	CD38 as a PET Imaging Target in Lung Cancer. Molecular Pharmaceutics, 2017, 14, 2400-2406.	4.6	25
31	Dose point kernels for 2,174 radionuclides. Medical Physics, 2019, 46, 5284-5293.	3.0	25
32	PET of Follicle-Stimulating Hormone Receptor: Broad Applicability to Cancer Imaging. Molecular Pharmaceutics, 2015, 12, 403-410.	4.6	23
33	ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2169-2179.	6.4	23
34	203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer. Current Medicinal Chemistry, 2020, 27, 7003-7031.	2.4	23
35	Uptake and retention of manganese contrast agents for PET and MRI in the rodent brain. Contrast Media and Molecular Imaging, 2016, 11, 371-380.	0.8	22
36	Preparation and in vivo characterization of 51MnCl2 as PET tracer of Ca2+ channel-mediated transport. Scientific Reports, 2017, 7, 3033.	3.3	22

#	Article	IF	Citations
37	PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor. Journal of Nuclear Medicine, 2015, 56, 758-763.	5.0	21
38	Nuclear excitation functions of proton-induced reactions (Ep= 35â€“90 MeV) from Fe, Cu, and Al. Nuclear Instruments & Methods in Physics Research B, 2016, 386, 44-53.	1.4	19
39	Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. Journal of Nuclear Medicine, 2021, 62, 3S-11S.	5.0	19
40	Evaluation of two novel 64Cu-labeled RGD peptide radiotracers for enhanced PET imaging of tumor integrin Î±vÎ²3. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1859-1868.	6.4	17
41	Evaluation of a chloride-based 89Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction resin. Nuclear Medicine and Biology, 2018, 64-65, 1-7.	0.6	17
42	Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Seminars in Radiation Oncology, 2021, 31, 37-44.	2.2	17
43	Imaging and dosimetric characteristics of ⁶⁷ Cu. Physics in Medicine and Biology, 2021, 66, 035002.	3.0	17
44	Excitation functions for (p,x) reactions of niobium in the energy range of Epâ€¯=â€¯40â€“90â€¯MeV. Nuclear Instruments & Methods in Physics Research B, 2018, 429, 53-74.	1.4	15
45	Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns. Journal of Nuclear Medicine, 2021, 62, 12S-22S.	5.0	14
46	Spot-welding solid targets for high current cyclotron irradiation. Applied Radiation and Isotopes, 2016, 118, 350-353.	1.5	13
47	Polyazamacrocycle Ligands Facilitate ⁸⁹Zr Radiochemistry and Yield ⁸⁹Zr Complexes with Remarkable Stability. Inorganic Chemistry, 2020, 59, 17473-17487.	4.0	13
48	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 12095.	4.1	13
49	Radiopharmaceutical Chemistry and Drug Developmentâ€”What's Changed?. Seminars in Radiation Oncology, 2021, 31, 3-11.	2.2	11
50	Addition of ¹³¹I-MIBG to PRRT (⁹⁰Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2021, 62, 1274-1277.	5.0	11
51	Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities. Journal of Nuclear Medicine, 2021, 62, 48S-59S.	5.0	11
52	The Impact of Radiopharmaceutical Therapy on Renal Function. Seminars in Nuclear Medicine, 2022, 52, 467-474.	4.6	9
53	Generation and Screening of Monoclonal Antibodies for ImmunoPET Imaging of IGF1R in Prostate Cancer. Molecular Pharmaceutics, 2014, 11, 3624-3630.	4.6	7
54	Development of a novel linearly-filled Derenzo microPET phantom. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 199-204.	1.0	7

#	Article	IF	Citations
55	Monte Carlo evaluation of hypothetical long axial fieldâ€ofâ€view PET scanner using GE Discovery MI PET frontâ€end architecture. Medical Physics, 2022, 49, 1139-1152.	3.0	7
56	Auger electron-based targeted radioimmunotherapy with 58mCo, a feasibility study. AIP Conference Proceedings, 2016, , .	0.4	6
57	Quantification of uptake in pelvis Fâ€18 FLT PETâ€CT images using a 3D localization and segmentation CNN. Medical Physics, 2022, 49, 1585-1598.	3.0	6
58	Absorbed dose distributions from betaâ€decaying radionuclides: Experimental validation of Monte Carlo tools for radiopharmaceutical dosimetry. Medical Physics, 2020, 47, 5779-5790.	3.0	5
59	Proton-induced reactions on Fe, Cu, and Ti from threshold to 55 MeV. European Physical Journal A, 2021, 57, 1.	2.5	5
60	SIR-Spheres activity measurements reveal systematic miscalibration. Journal of Nuclear Medicine, 2022, , jnumed.121.262650.	5.0	5
61	Half-life of Mn51. Physical Review C, 2017, 96, .	2.9	4
62	Simplified and reproducible radiochemical separations for the production of high specific activity 61Cu, 64Cu, 86Y and 55Co. AIP Conference Proceedings, 2017, , .	0.4	3
63	Half-life of ⁶⁷Cu. Journal of Physics Communications, 2021, 5, 085007.	1.2	3
64	Radiobromine production, isolation and radiosynthesis for the development of a novel prostate cancer radiotherapeutic agent. AIP Conference Proceedings, 2017, , .	0.4	2
65	Earth, air, fire and water: A targetry quartet. AIP Conference Proceedings, 2017, , .	0.4	1
66	Development and characterization of a hexamodal imaging nanoparticle. , 2015, , .		0
67	Practical Considerations for Implementation of¹⁷⁷Lu-DOTATATE Neuroendocrine Tumor Treatment Programs. Journal of Nuclear Medicine Technology, 2022, 50, 195-202.	0.8	0